enGene Therapeutics ENGN
NASDAQ ENGN
$1.56 -0.02 (-1.27%)
At close: Oct 23, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Cash & Current Investments (2022 - 2026)

Updated

enGene Therapeutics (ENGN) posted Cash & Current Investments of $266.32 million for fiscal Q3 2026 (quarter ended Jul 31, 2026), up 31.9% from $201.91 million a year earlier and up 3.0% from the prior quarter.

Analysis

enGene Therapeutics (ENGN) Cash & Current Investments (2022 - 2026) Analysis & Trends

At the end of FY2025 (ended Oct 31, 2025), enGene Therapeutics' Cash & Current Investments came in at $193.74 million, down 18.7% from FY2024.

  • Annual Cash & Current Investments shows a three-year compound annual growth rate of 111.7% (FY2022 to FY2025).
  • In prior fiscal years, enGene Therapeutics' Cash & Current Investments was $238.33 million in FY2024 (+192.4%), $81.52 million in FY2023 (+298.9%) and $20.43 million in FY2022.
  • Quarterly Cash & Current Investments has run from a low of $20.43 million in fiscal Q4 2022 to a high of $275.95 million in fiscal Q1 2026 over five years.
  • On a year-over-year basis, Cash & Current Investments has increased in each of the last three quarters, with growth averaging 45.4% over the last eight quarters.
  • The strongest year-over-year quarter for Cash & Current Investments in the past five years was fiscal Q4 2023, with growth of 298.9%; the weakest was fiscal Q3 2025, with a decline of 21.6%.
  • According to Business Quant data, Cash & Current Investments for the three prior fiscal quarters was $258.47 million (Q2 2026), $275.95 million (Q1 2026) and $193.74 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 17.23 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 6.57 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 7.14 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 7.69 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 4.90 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 3.18 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 11.70 Bn
10 enGene Therapeutics 109.41 Mn -885.06 Mn - 266.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 31, 2026 266.32 Mn
Apr 30, 2026 258.47 Mn
Jan 31, 2026 275.95 Mn
Oct 31, 2025 193.74 Mn
Jul 31, 2025 201.91 Mn
Apr 30, 2025 217.39 Mn
Jan 31, 2025 213.81 Mn
Oct 31, 2024 238.33 Mn
Jul 31, 2024 257.68 Mn
Apr 30, 2024 264.81 Mn
Jan 31, 2024 85.65 Mn
Oct 31, 2023 81.52 Mn
Oct 31, 2022 20.43 Mn
API Access

enGene Therapeutics Cash & Current Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-current-investments&ticker=ENGN&period=max&api_key=YOUR_API_KEY